Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female age 18 to 49 years (inclusive) for the Phase 1 group, or 50 to 64 years (inclusive) for the Phase 2 group at the time of enrollment into the study.~* Able and willing to complete the informed consent process.~* Available for clinical follow-up through the last study visit at 6 months after the study vaccination.~* In good general health as determined by medical history, vital signs, physical examination, and clinical judgment of the investigator.~* Screening laboratory values must be within the central laboratory normal limits prior to study enrollment. Minor abnormalities are considered acceptable if not clinically significant.~* Willing to have blood samples collected, stored indefinitely, and used for research purposes.~* Able to provide proof of identity to the satisfaction of the study staff completing the enrollment process.~* Negative pregnancy test (urine and serum) for women of childbearing potential.~Exclusion Criteria:~* Previous pneumococcal disease (either confirmed or by self-reporting).~* Previous receipt of a licensed or investigational pneumococcal vaccine.~* Receipt of any investigational study product within 30 days prior to enrollment into the study, currently participating in another interventional investigational study, or having plans to receive another investigational product(s) while on study.~* Planned or actual administration of any licensed vaccine during the period starting 30 days before enrollment into the study through Day 29.~* Physical examination indicating any clinically significant medical condition.~* Body Temperature \> 38.0°C (\> 100.4°F) or acute illness within 3 days prior to study vaccination (subject may be rescheduled).~* Seropositive to HIV, HCV, or HBsAg.~* History of severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis.~* Female who is breast-feeding or planning to become pregnant during study participation.~* Bleeding disorder diagnosed by a doctor (eg, factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws.~* Any other chronic or clinically significant medical condition that, in the opinion of the investigator, would jeopardize the safety or rights of the subject or confound evaluation of the study vaccine.~* Any medical, psychiatric, or social condition that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a subject's ability to give informed consent.~* Received blood or blood product (including Immune Globulin IV) within 90 days prior to enrollment into the study.~* Received systemic corticosteroids for ≥ 14 consecutive days and has not completed treatment ≤30 days prior to enrollment into the study.~* Receiving immunosuppressive therapy.~* History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- VAX-24 Low Dose (Type: EXPERIMENTAL): Participants will receive a single dose of VAX-24 1.1 mcg administered as an intramuscular injection on Day 1.
- VAX-24 Mid Dose (Type: EXPERIMENTAL): Participants will receive a single dose of VAX-24 2.2 mcg administered as an intramuscular injection on Day 1.
- VAX-24 Mixed Dose (Type: EXPERIMENTAL): Participants will receive a single dose of VAX-24 2.2 mcg/4.4 mcg administered as an intramuscular injection on Day 1.
- PCV20 (Type: ACTIVE_COMPARATOR): Participants will receive a single intramuscular injection of the standard dose of PCV20 on Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete